Search

Your search keyword '"Di Fusco S"' showing total 4 results
Start Over Author "Di Fusco S" Publisher il pensiero scientifico editore
4 results on '"Di Fusco S"'

1. Multidistrict atherosclerotic disease: epidemiological and clinical framework

Author

Di Fusco, S, Abrignani, M, Amico, A, Luca, F, Mureddu, G, Ceravolo, R, Temporelli, P, Acerbo, V, Altamura, V, Baccino, D, Binaghi, G, Bugani, G, Cesaro, A, Ciccirillo, F, Cocozza, S, D'Errigo, P, Di Martino, M, Di Nora, C, Fileti, L, Lopriore, V, Maloberti, A, Monitillo, F, Gulizia, M, Grimaldi, M, Gabrielli, D, Oliva, F, Colivicchi, F, Di Fusco S. A., Abrignani M. G., Amico A. F., Luca F., Mureddu G. F., Ceravolo R., Temporelli P. L., Acerbo V., Altamura V., Baccino D., Binaghi G., Bugani G., Cesaro A., Ciccirillo F., Cocozza S., D'Errigo P., Di Martino M., Di Nora C., Fileti L., Lopriore V., Maloberti A., Monitillo F., Gulizia M. M., Grimaldi M., Gabrielli D., Oliva F., Colivicchi F., Di Fusco, S, Abrignani, M, Amico, A, Luca, F, Mureddu, G, Ceravolo, R, Temporelli, P, Acerbo, V, Altamura, V, Baccino, D, Binaghi, G, Bugani, G, Cesaro, A, Ciccirillo, F, Cocozza, S, D'Errigo, P, Di Martino, M, Di Nora, C, Fileti, L, Lopriore, V, Maloberti, A, Monitillo, F, Gulizia, M, Grimaldi, M, Gabrielli, D, Oliva, F, Colivicchi, F, Di Fusco S. A., Abrignani M. G., Amico A. F., Luca F., Mureddu G. F., Ceravolo R., Temporelli P. L., Acerbo V., Altamura V., Baccino D., Binaghi G., Bugani G., Cesaro A., Ciccirillo F., Cocozza S., D'Errigo P., Di Martino M., Di Nora C., Fileti L., Lopriore V., Maloberti A., Monitillo F., Gulizia M. M., Grimaldi M., Gabrielli D., Oliva F., and Colivicchi F.

Abstract

Atherosclerosis is a systemic disease that can involve different arterial districts. Traditionally, the focus of cardiologists has been on the diagnosis and treatment of atherosclerotic coronary artery disease (CAD). However, atherosclerosis localization in other districts is increasingly common and is associated with an increased risk of CAD and, more generally, of adverse cardiovascular events. Although the term peripheral arterial disease (PAD) commonly refers to the localization of atherosclerotic disease in the arterial districts of the lower limbs, in this document, in accordance with the European Society of Cardiology guidelines, the term PAD will be used for all the locations of atherosclerotic disease excluding coronary and aortic ones. The aim of this review is to report updated data on PAD epidemiology, with particular attention to the prevalence and its prognostic impact on patients with CAD. Furthermore, the key points for an appropriate diagnostic framework and a correct pharmacological therapeutic approach are summarized, while surgical/interventional treatment goes beyond the scope of this review.

Published
2024

2. ANMCO/SICI-GISE/SIC/SIECVI/SIRM Consensus document: Appropriateness of multimodality imaging in cardiovascular disease [Documento di consenso ANMCO/SICI-GISE/SIC/SIECVI/SIRM: Appropriatezza dell’imaging multimodale nelle patologie cardiovascolari]

Author

Nardi, F, Pino, P, Gabrielli, D, Colivicchi, F, Abrignani, M, Amico, A, Aspromonte, N, Benedetto, F, Bertella, E, Boccardi, L, Bucciarelli Ducci, C, Caldarola, P, Campana, M, Caso, P, Citro, R, Costante, A, De Chiara, B, Di Cesare, E, Di Fusco, S, Domenicucci, S, Enea, I, Erba, P, Faganello, G, Favilli, S, Geraci, G, Giubbini, R, Giunta, N, Guido, V, Imazio, M, Khoury, G, La Canna, G, Mele, D, Moreo, A, Mercuro, G, Musumeci, G, Neglia, D, Parrini, I, Pinamonti, B, Pollarolo, L, Pontone, G, Privitera, C, Riccio, C, Sinagra, G, Urbinati, S, Varbella, F, Berisso, M, Zuin, G, Di Lenarda, A, Gulizia, M, Nardi F., Pino P. G., Gabrielli D., Colivicchi F., Abrignani M. G., Amico A. F., Aspromonte N., Benedetto F. A., Bertella E., Boccardi L. M., Bucciarelli Ducci C., Caldarola P., Campana M., Caso P., Citro R., Costante A. M., De Chiara B. C., Di Cesare E., Di Fusco S. A., Domenicucci S., Enea I., Erba P., Faganello G., Favilli S., Geraci G., Giubbini R., Giunta N., Guido V., Imazio M., Khoury G., La Canna G., Mele D., Moreo A. M., Mercuro G. G., Musumeci G., Neglia D., Parrini I., Pinamonti B., Pollarolo L., Pontone G., Privitera C., Riccio C., Sinagra G., Urbinati S., Varbella F., Berisso M. Z., Zuin G., Di Lenarda A., Gulizia M. M., Nardi, F, Pino, P, Gabrielli, D, Colivicchi, F, Abrignani, M, Amico, A, Aspromonte, N, Benedetto, F, Bertella, E, Boccardi, L, Bucciarelli Ducci, C, Caldarola, P, Campana, M, Caso, P, Citro, R, Costante, A, De Chiara, B, Di Cesare, E, Di Fusco, S, Domenicucci, S, Enea, I, Erba, P, Faganello, G, Favilli, S, Geraci, G, Giubbini, R, Giunta, N, Guido, V, Imazio, M, Khoury, G, La Canna, G, Mele, D, Moreo, A, Mercuro, G, Musumeci, G, Neglia, D, Parrini, I, Pinamonti, B, Pollarolo, L, Pontone, G, Privitera, C, Riccio, C, Sinagra, G, Urbinati, S, Varbella, F, Berisso, M, Zuin, G, Di Lenarda, A, Gulizia, M, Nardi F., Pino P. G., Gabrielli D., Colivicchi F., Abrignani M. G., Amico A. F., Aspromonte N., Benedetto F. A., Bertella E., Boccardi L. M., Bucciarelli Ducci C., Caldarola P., Campana M., Caso P., Citro R., Costante A. M., De Chiara B. C., Di Cesare E., Di Fusco S. A., Domenicucci S., Enea I., Erba P., Faganello G., Favilli S., Geraci G., Giubbini R., Giunta N., Guido V., Imazio M., Khoury G., La Canna G., Mele D., Moreo A. M., Mercuro G. G., Musumeci G., Neglia D., Parrini I., Pinamonti B., Pollarolo L., Pontone G., Privitera C., Riccio C., Sinagra G., Urbinati S., Varbella F., Berisso M. Z., Zuin G., Di Lenarda A., and Gulizia M. M.

Abstract

The complexity of cardiovascular diseases has led to an extensive use of technological instruments and the development of multimodality imaging. This extensive use of different cardiovascular imaging tests in the same patient has increased costs and waiting times.The concept of appropriateness has changed over time. Appropriateness criteria address the need for specific cardiovascular imaging tests in well-defined clinical scenarios, and define the kind of cardiovascular imaging that is appropriated for each clinical scenario in different stages of the disease. The concept of appropriateness criteria has replaced the old idea of appropriate use criteria and reflects the increasing effort of the international Scientific Societies to create and review in a critical way the management of diagnostic tests used by clinicians.The aim of this Italian consensus document is to address the use of multimodality imaging in the diagnosis and management of the major cardiovascular clinical scenarios, taking into consideration not only the international guidelines and scientific documents already published, but also the reality of Italian laws as well as the various professional profiles involved in patient management and availability of technological diagnostic instruments.

Published
2020

3. [ANMCO Position paper: Amyloidosis for the clinical cardiologist. A "clinical primer" from the ANMCO Rare Disease Working Group].

Author

Chimenti C, Grego S, Di Fusco S, De Luca L, Caldarola P, Cannillo M, Cipriani M, Di Lenarda A, Donato D, Leone S, Limongelli G, Navazio A, Riccio C, Valente S, Gulizia MM, Gabrielli D, Oliva F, and Colivicchi F

Subjects
Humans, Prealbumin therapeutic use, Amyloid therapeutic use, Rare Diseases, Amyloid Neuropathies, Familial complications, Amyloid Neuropathies, Familial diagnosis, Amyloid Neuropathies, Familial genetics, Cardiologists
Abstract

Cardiac amyloidosis, in the three forms of immunoglobulin light chain (AL), transthyretin (ATTR) wild type (ATTRwt) and mutated (ATTRv) amyloidosis, is an increasingly known and recognized disease in the cardiovascular setting. The first stage of the patient's journey is the clinical suspicion of the disease, which is placed, in presence of a hypertrophic phenotype, by the identification of red flags, both extracardiac and cardiac clues whose presence increase the probability of being faced with a patient with this disease. The second stage is represented by diagnosis, which occurs with certainty through the identification of amyloid substance in cardiac tissue. This stage is spotted in wo parts, i.e. disease confirmation and disease etiology definition (AL vs ATTRwt vs ATTRv). However, it is possible in some selected cases to make a diagnosis of ATTR without the need for tissue assessment, in presence of a positive grade 2-3 bisphosphonate scintigraphy and absence of monoclonal component. Once the diagnosis has been made, the third stage is the assessment of prognosis, the fourth is the patient therapy pathway and fifth is the follow-up plan. Prognosis evaluation is based on different staging systems at the onset of the disease, whose applicability in the era of new effective therapies is still to be defined. To date, the transthyretin tetramer stabilizer tafamidis is the only approved treatment for both wild-type and mutant ATTR cardiomyopathy without polyneuropathy, while ATTRv with associated neuropathy can benefit from treatment with patisiran, an inhibitor of hepatic protein synthesis. Therapies for complications and comorbidities, must be addressed individually, due to the lack of specific clinical trials on this category of patients. In fact, it is important to take into consideration the risks linked to the use of some drugs due to the infiltration of the conduction tissue by the amyloid substance, which increases the risk of bradycardia and heart blocks, the tendency towards hypotension and the increased thromboembolic risk. It is also essential to follow the course of the disease and the efficacy of the treatment in affected patients with a standardized follow-up, and to identify early the signs/symptoms of the disease in asymptomatic TTR mutation carriers.This ANMCO position paper on amyloidosis aims to provide the clinical cardiologist with a practical summary of the disease, to accompany the patient with amyloidosis in the various stages of his journey.

Published
2023
Full Text
View/download PDF

4. [ANMCO/GISE/SICCH Inter-Society Consensus Document: Antithrombotic therapy after surgery or structural interventional procedures for valvular heart diseases: how to treat postoperative complications].

Author

Patanè L, Di Lenarda A, Aspromonte N, Bianca I, Capranzano P, Di Eusanio M, Di Fusco S, Di Tano G, Gabrielli D, Garatti A, Geraci G, Gerometta P, Miceli A, Montalto A, Musumeci F, Musumeci G, Nardi F, Parolari A, Pino PG, Rubino AS, Savini C, Troise G, Tarantini G, Urbinati S, Varbella F, and Gulizia MM

Subjects
Anticoagulants administration & dosage, Consensus, Female, Heart Valve Prosthesis Implantation adverse effects, Heart Valve Prosthesis Implantation methods, Humans, Postoperative Complications physiopathology, Pregnancy, Pregnancy Complications, Cardiovascular surgery, Thromboembolism etiology, Thromboembolism prevention & control, Fibrinolytic Agents administration & dosage, Heart Valve Diseases surgery, Postoperative Complications drug therapy, Practice Guidelines as Topic
Abstract

Continuous improvement of technologies, devices and drugs needs a renewal and update of current recommendations and guidelines on antithrombotic strategies, especially in those fields where literature lacks of established scientific evidences. Accordingly, the aim of this consensus statement is to provide support for antithrombotic therapy based on current guidelines and the most recent scientific evidences.After an overview on the currently available devices, the appropriate therapy according to type of procedure and implanted device is discussed. The occurrence of postoperative thromboembolic and/or hemorrhagic complications is analyzed, along with the appropriate diagnostic tools and therapeutic approach. A section is dedicated to counseling to pregnancy in women with heart valve prosthesis. Finally, the role of novel oral anticoagulants is discussed, and indications are provided for the management of patients undergoing surgery or interventional procedures on oral anticoagulation therapy.

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results